Table 3 Follow-up period, number of events and incidence per 1000 person-years
Event | Lispro(n = 1986) | Aspart(n = 14,501) | Glulisine(n = 1133) |
|---|---|---|---|
Deaths | 93 (234.4) | 1192 (284.9) | 33 (156.7) |
Fatal CHD | 29 (73.1) | 352 (84.1) | 13 (61.7) |
Fatal CVD | 34 (85.7) | 424 (101.3) | 14 (66.5) |
CHD | 196 (546.9) | 1896 (489.9) | 110 (571.9) |
CVD | 234 (668.4) | 2312 (622.4) | 132 (699.5) |
Stroke | 39 (99.7) | 412 (100.1) | 11 (52.6) |
Heart failure | 109 (289.0) | 1177 (295.5) | 46 (225.7) |
Kidney failure | 75 (193.8) | 708 (173.4) | 28 (135.8) |
Hypoglycemia | 15 (38.1) | 234 (56.5) | 12 (57.6) |
Hyperglycemia | 10 (25.3) | 190 (45.8) | 7 (33.4) |
Maximum follow up time, years | 6.3 | 6.4 | 6.1 |
Mean follow up time, years | 2.0 | 2.9 | 1.9 |
Median follow up time, years | 1.3 | 2.9 | 1.8 |